Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

"iTeos to shut down following $2bn GSK-partnered TIGIT asset failure" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

iTeos and GSK terminate belrestotug program after GALAXIES Lung-201 results fail to show significant progression-free survival improvements.

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

ITeos Therapeutics plans to wind down its operations and sell its assets, including experimental cancer treatments and an obesity drug, the company said on Wednesday, two weeks after its lead drug ...

GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with iTeos Therapeutics for ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK ...

Both GSK and iTeos will be ending all belrestotug-related studies, including a late-stage study that was currently enrolling study participants.